Skip to main content

Table 1 Clinical characteristics of the subjects enrolled

From: Evaluation of vascular quality of life questionnaire in dialysis patients with peripheral arterial disease treated by low-density lipoprotein apheresis

  Non-CLI (n = 17) CLI (n = 15) P value
Age (years) 70.4 ± 8.0 72.0 ± 7.6 0.57
Gender (male/female) 15/2 9/6 0.08
Body mass index (kg/m2) 20.9 ± 2.6 23.4 ± 3.7 0.04
Diabetes mellitus (n, %) 11, 64.7 % 15, 100 % 0.01
Cardiovascular disease (n, %) 14, 82.4 % 14, 93.3 % 0.35
Cerebrovascular disease (n, %) 5, 29.4 % 5, 33.3 % 0.56
Duration of hemodialysis (years) 10.6 ± 9.1 9.9 ± 8.4 0.98
Laboratory data    
 Total cholesterol (mg/dL) 161.2 ± 41.3 178.5 ± 46.3 0.24
 Triglyceride (mg/dL) 98.1 ± 78.5 127.6 ± 48.0 0.03
 High-density lipoprotein cholesterol (mg/dL) 52.1 ± 15.2 52.1 ± 14.0 0.99
 C-reactive protein (mg/dL) 0.34 ± 0.63 0.44 ± 0.66 0.30
 Albumin (g/dL) 3.51 ± 0.32 3.43 ± 0.28 0.46
Medications    
 Statin (n, %) 4, 23.5 % 8, 53.3 % 0.08
 Erythropoietin, darbepoetin alfa (n, %) 8, 47.1 % 7, 46.7 % 0.98
 Erythropoietin, epoetin beta pegol (n, %) 5, 29.4 % 5, 33.3 % 0.81
 Anti-platelet (n, %) 17, 100 % 15, 100 % N/A
 Warfarin (n, %) 2, 11.8 % 4, 26.7 % 0.27
 Anti-hypertensive, ARB (n, %) 2, 11.8 % 1, 6.7 % 0.55
 Anti-hypertensive, Ca antagonist (n, %) 4, 23.5 % 4, 26.7 % 0.58
 Anti-hypertensive, Beta blocker (n, %) 3, 17.6 % 5, 33.3 % 0.27
 Anti-hypertensive, Alpha blocker (n, %) 2, 11.8 % 0, 0 % 0.27
  1. ARB angiotensin II receptor blocker, Ca calcium, N/A not applicable